Systematic dissection of dysregulated transcription factor–miRNA feed-forward loops across tumor types

Transcription factor and microRNA (miRNA) can mutually regulate each other and jointly regulate their shared target genes to form feed-forward loops (FFLs). While there are many studies of dysregulated FFLs in a specific cancer, a systematic investigation of dysregulated FFLs across multiple tumor types (pan-cancer FFLs) has not been performed yet. In this study, using The Cancer Genome Atlas data, we identified 26 pan-cancer FFLs, which were dysregulated in at least five tumor types. These pan-cancer FFLs could communicate with each other and form functionally consistent subnetworks, such as epithelial to mesenchymal transition-related subnetwork. Many proteins and miRNAs in each subnetwork belong to the same protein and miRNA family, respectively. Importantly, cancer-associated genes and drug targets were enriched in these pan-cancer FFLs, in which the genes and miRNAs also tended to be hubs and bottlenecks. Finally, we identified potential anticancer indications for existing drugs with novel mechanism of action. Collectively, this study highlights the potential of pan-cancer FFLs as a novel paradigm in elucidating pathogenesis of cancer and developing anticancer drugs.

[1]  Hui Yu,et al.  EW_dmGWAS: edge-weighted dense module search for genome-wide association studies and gene expression profiles , 2015, Bioinform..

[2]  How-Ran Guo,et al.  Arsenic trioxide induces programmed cell death through stimulation of ER stress and inhibition of the ubiquitin-proteasome system in human sarcoma cells. , 2015, Cancer letters.

[3]  Peilin Jia,et al.  Clinically relevant genes and regulatory pathways associated with NRASQ61 mutations in melanoma through an integrative genomics approach , 2014, Oncotarget.

[4]  An-Yuan Guo,et al.  Transcription factor and microRNA co-regulatory loops: important regulatory motifs in biological processes and diseases , 2015, Briefings Bioinform..

[5]  B. Zhai,et al.  Arsenic trioxide potentiates the anti-cancer activities of sorafenib against hepatocellular carcinoma by inhibiting Akt activation , 2015, Tumor Biology.

[6]  Chirayu Pankaj Goswami,et al.  PROGgeneV2: enhancements on the existing database , 2014, BMC Cancer.

[7]  M. Lupien,et al.  A global assessment of cancer genomic alterations in epigenetic mechanisms , 2014, Epigenetics & Chromatin.

[8]  Marco F. Schmidt,et al.  Drug target miRNAs: chances and challenges. , 2014, Trends in biotechnology.

[9]  Zhongming Zhao,et al.  Reproducible combinatorial regulatory networks elucidate novel oncogenic microRNAs in non-small cell lung cancer , 2014, RNA.

[10]  P. Meng,et al.  Transcription addiction: can we garner the Yin and Yang functions of E2F1 for cancer therapy? , 2014, Cell Death and Disease.

[11]  Zhongming Zhao,et al.  Quantitative network mapping of the human kinome interactome reveals new clues for rational kinase inhibitor discovery and individualized cancer therapy , 2014, Oncotarget.

[12]  Judy H. Cho,et al.  Guilt by rewiring: gene prioritization through network rewiring in genome wide association studies. , 2014, Human molecular genetics.

[13]  David S. Wishart,et al.  DrugBank 4.0: shedding new light on drug metabolism , 2013, Nucleic Acids Res..

[14]  David J. Arenillas,et al.  JASPAR 2014: an extensively expanded and updated open-access database of transcription factor binding profiles , 2013, Nucleic Acids Res..

[15]  David A. Frank,et al.  Targeting transcription factors: promising new strategies for cancer therapy , 2013, Current opinion in oncology.

[16]  Min Zhao,et al.  Synergetic regulatory networks mediated by oncogene-driven microRNAs and transcription factors in serous ovarian cancer. , 2013, Molecular bioSystems.

[17]  R. Dahiya,et al.  microRNA-183 is an oncogene targeting Dkk-3 and SMAD4 in prostate cancer , 2013, British Journal of Cancer.

[18]  Xia Li,et al.  SM2miR: a database of the experimentally validated small molecules' effects on microRNA expression , 2013, Bioinform..

[19]  Zhiguo Zhang,et al.  Histone chaperones in nucleosome assembly and human disease , 2013, Nature Structural &Molecular Biology.

[20]  H. Zhang,et al.  Regulatory role of KEAP1 and NRF2 in PPARγ expression and chemoresistance in human non-small-cell lung carcinoma cells. , 2012, Free radical biology & medicine.

[21]  Zhongming Zhao,et al.  Uncovering MicroRNA and Transcription Factor Mediated Regulatory Networks in Glioblastoma , 2012, PLoS Comput. Biol..

[22]  Martin Reczko,et al.  DIANA miRPath v.2.0: investigating the combinatorial effect of microRNAs in pathways , 2012, Nucleic Acids Res..

[23]  Parantu K. Shah,et al.  Integrative analysis of gene and miRNA expression profiles with transcription factor–miRNA feed-forward loops identifies regulators in human cancers , 2012, Nucleic acids research.

[24]  Angela M. Liu,et al.  Circulating miR-15b and miR-130b in serum as potential markers for detecting hepatocellular carcinoma: a retrospective cohort study , 2012, BMJ Open.

[25]  An-Yuan Guo,et al.  MicroRNA and transcription factor co-regulatory network analysis reveals miR-19 inhibits CYLD in T-cell acute lymphoblastic leukemia , 2012, Nucleic acids research.

[26]  Q. Cui,et al.  Sulindac inhibits tumor cell invasion by suppressing NF-κB mediated transcription of microRNAs , 2012, Oncogene.

[27]  Wen-Hui Su,et al.  IGDB.NSCLC: integrated genomic database of non-small cell lung cancer , 2011, Nucleic Acids Res..

[28]  Nectarios Koziris,et al.  TarBase 6.0: capturing the exponential growth of miRNA targets with experimental support , 2011, Nucleic Acids Res..

[29]  David G Johnson,et al.  Transcriptional and nontranscriptional functions of E2F1 in response to DNA damage. , 2012, Cancer research.

[30]  X. Liu,et al.  Overexpression of members of the microRNA-183 family is a risk factor for lung cancer: A case control study , 2011, BMC Cancer.

[31]  Hongyu Zhao,et al.  COSINE: COndition-SpecIfic sub-NEtwork identification using a global optimization method , 2011, Bioinform..

[32]  E. Barillot,et al.  Asf1b, the necessary Asf1 isoform for proliferation, is predictive of outcome in breast cancer , 2011, The EMBO journal.

[33]  Chi-Hung Lin,et al.  NSCLC : integrated genomic database of non-small cell lung cancer , 2011 .

[34]  Youhong Liu,et al.  Activation of the p38 MAPK/Akt/ERK1/2 signal pathways is required for the protein stabilization of CDC6 and cyclin D1 in low‐dose arsenite‐induced cell proliferation , 2010, Journal of cellular biochemistry.

[35]  Anjali J. Koppal,et al.  Supplementary data: Comprehensive modeling of microRNA targets predicts functional non-conserved and non-canonical sites , 2010 .

[36]  S. Safe,et al.  Arsenic trioxide downregulates specificity protein (Sp) transcription factors and inhibits bladder cancer cell and tumor growth. , 2010, Experimental cell research.

[37]  A. Fuente,et al.  From ‘differential expression’ to ‘differential networking’ – identification of dysfunctional regulatory networks in diseases , 2010 .

[38]  Ronald Abraham,et al.  Association of microRNA expression with microsatellite instability status in colorectal adenocarcinoma. , 2010, The Journal of molecular diagnostics : JMD.

[39]  Yu Cao,et al.  NSAID sulindac and its analog bind RXRalpha and inhibit RXRalpha-dependent AKT signaling. , 2010, Cancer cell.

[40]  Jian-Hua Tong,et al.  Arsenic Trioxide Controls the Fate of the PML-RARα Oncoprotein by Directly Binding PML , 2010, Science.

[41]  Mark D. Robinson,et al.  edgeR: a Bioconductor package for differential expression analysis of digital gene expression data , 2009, Bioinform..

[42]  Ming Lu,et al.  TransmiR: a transcription factor–microRNA regulation database , 2009, Nucleic Acids Res..

[43]  A. G. de la Fuente.  From 'differential expression' to 'differential networking' - identification of dysfunctional regulatory networks in diseases. , 2010, Trends in genetics : TIG.

[44]  Thomas Streichert,et al.  Identification of differentially expressed microRNAs in human male breast cancer , 2010, BMC Cancer.

[45]  An-Yuan Guo,et al.  A Novel microRNA and transcription factor mediated regulatory network in schizophrenia , 2010, BMC Systems Biology.

[46]  C. Croce,et al.  MicroRNAs in cancer: small molecules with a huge impact. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[47]  Shih-Yin Tsai,et al.  Emerging roles of E2Fs in cancer: an exit from cell cycle control , 2009, Nature Reviews Cancer.

[48]  C. Burge,et al.  Most mammalian mRNAs are conserved targets of microRNAs. , 2008, Genome research.

[49]  V. Bae-Jump,et al.  Arsenic Trioxide (As2O3) Inhibits Expression of Estrogen Receptor—alpha Through Regulation of the Mitogen-activated Protein Kinase (MAPK) Pathway in Endometrial Cancer Cells , 2008, Reproductive Sciences.

[50]  C. Rhee,et al.  A combination of sulindac and arsenic trioxide synergistically induces apoptosis in human lung cancer H1299 cells via c-Jun NH2-terminal kinase-dependent Bcl-xL phosphorylation. , 2008, Lung cancer.

[51]  Robert A. Weinberg,et al.  Epithelial-mesenchymal transition: at the crossroads of development and tumor metastasis. , 2008, Developmental cell.

[52]  Sun-Mi Park,et al.  The miR-200 family determines the epithelial phenotype of cancer cells by targeting the E-cadherin repressors ZEB1 and ZEB2. , 2008, Genes & development.

[53]  P. Adamson,et al.  Phase 1 trial and pharmacokinetic study of arsenic trioxide in children and adolescents with refractory or relapsed acute leukemia, including acute promyelocytic leukemia or lymphoma. , 2008, Blood.

[54]  Fidel Ramírez,et al.  Computing topological parameters of biological networks , 2008, Bioinform..

[55]  Brad T. Sherman,et al.  Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources , 2008, Nature Protocols.

[56]  Yitzhak Pilpel,et al.  Global and Local Architecture of the Mammalian microRNA–Transcription Factor Regulatory Network , 2007, PLoS Comput. Biol..

[57]  A. van Oudenaarden,et al.  MicroRNA-mediated feedback and feedforward loops are recurrent network motifs in mammals. , 2007, Molecular cell.

[58]  Héctor Peinado,et al.  Snail, Zeb and bHLH factors in tumour progression: an alliance against the epithelial phenotype? , 2007, Nature Reviews Cancer.

[59]  Mark Gerstein,et al.  The Importance of Bottlenecks in Protein Networks: Correlation with Gene Essentiality and Expression Dynamics , 2007, PLoS Comput. Biol..

[60]  Chih-Hung Hsu,et al.  Arsenic trioxide in patients with hepatocellular carcinoma: a phase II trial , 2006, Investigational New Drugs.

[61]  Petr Vaňhara,et al.  Jun: the master regulator in healthy and cancer cells , 2006 .

[62]  T. Libermann,et al.  Targeting transcription factors for cancer gene therapy. , 2006, Current gene therapy.

[63]  Alexander E. Kel,et al.  TRANSFAC® and its module TRANSCompel®: transcriptional gene regulation in eukaryotes , 2005, Nucleic Acids Res..

[64]  P. Hinds,et al.  Cyclins and cdks in development and cancer: a perspective , 2005, Oncogene.

[65]  C. Burge,et al.  Conserved Seed Pairing, Often Flanked by Adenosines, Indicates that Thousands of Human Genes are MicroRNA Targets , 2005, Cell.

[66]  Chao-yuan Huang,et al.  Characterization of molecular events in a series of bladder urothelial carcinoma cell lines with progressive resistance to arsenic trioxide , 2004, Anti-cancer drugs.

[67]  T. Hubbard,et al.  A census of human cancer genes , 2004, Nature Reviews Cancer.

[68]  A. Barabasi,et al.  Network biology: understanding the cell's functional organization , 2004, Nature Reviews Genetics.

[69]  D. Bartel.  MicroRNAs Genomics, Biogenesis, Mechanism, and Function , 2004, Cell.

[70]  Hee-kyoung Kang,et al.  Arsenic trioxide-induced apoptosis is independent of stress-responsive signaling pathways but sensitive to inhibition of inducible nitric oxide synthase in HepG2 cells , 2003, Experimental & Molecular Medicine.

[71]  Keunchil Park,et al.  Arsenic trioxide inhibits the growth of A498 renal cell carcinoma cells via cell cycle arrest or apoptosis. , 2003, Biochemical and biophysical research communications.

[72]  J. Darnell.  Transcription factors as targets for cancer therapy , 2002, Nature Reviews Cancer.

[73]  Janet S. Lee,et al.  Mechanisms of action of arsenic trioxide. , 2002, Cancer research.

[74]  Benno Schwikowski,et al.  Discovering regulatory and signalling circuits in molecular interaction networks , 2002, ISMB.

[75]  Guoqiang Chen,et al.  Expanding the use of arsenic trioxide: leukemias and beyond. , 2002, Seminars in hematology.

[76]  Michael J Thun,et al.  Nonsteroidal anti-inflammatory drugs as anticancer agents: mechanistic, pharmacologic, and clinical issues. , 2002, Journal of the National Cancer Institute.

[77]  Guoqiang Chen,et al.  Arsenic trioxide, a therapeutic agent for APL , 2001, Oncogene.

[78]  O. Ogawa,et al.  Tumor growth inhibition by arsenic trioxide (As2O3) in the orthotopic metastasis model of androgen-independent prostate cancer. , 2001, Cancer research.

[79]  Zhen-yi Wang,et al.  RESPONSE: re: apoptosis and growth inhibition in malignant lymphocytes after treatment with arsenic trioxide at clinically achievable concentrations , 1999, Journal of the National Cancer Institute.

[80]  Yong-kui,et al.  Apoptosis and growth inhibition in malignant lymphocytes after treatment with arsenic trioxide at clinically achievable concentrations. , 1999, Journal of the National Cancer Institute.

[81]  D. Latchman.  Transcription factors: an overview. , 1997, The international journal of biochemistry & cell biology.